The study, published in JAMA Dermatology, centers on a technology known as line-field confocal optical coherence tomography, or LC-OCT. This imaging platform merges two established techniques into a single device. The first is optical coherence tomography, commonly abbreviated OCT, which uses low-coherence light to capture cross-sectional images of tissue and provides reliable information about the thickness and lateral extent of a tumor. The second is line-field confocal microscopy, which delivers sharply resolved images at the cellular level, allowing clinicians to examine individual cell structures within the upper layers of the skin without taking a biopsy.

The combination is what gives LC-OCT its unusual diagnostic power. Whereas OCT alone offers depth but limited cellular detail, and confocal microscopy alone offers cellular detail but limited depth, the hybrid technique produces vertical, horizontal and fully three-dimensional images of the skin in real time, with a resolution on the order of micrometers, that is, thousandths of a millimeter. For perspective, a single human hair is roughly 50 micrometers thick. The result is a live, non-invasive window into the architecture of the skin that approaches what a pathologist would see under a microscope, but without cutting, staining or waiting for laboratory processing.

LC-OCT is already in clinical use as a standard tool for detecting basal cell carcinoma in its early stages and for monitoring how well non-invasive therapies are working. What the FAU team has added is a layer of artificial intelligence trained to interpret the images. The AI analyzes the optical data as it is acquired and overlays a color-coded probability value onto the image, indicating the likelihood that basal cell carcinoma is present in each region examined. This allows the physician to recognize suspicious areas at a glance, dramatically reducing the cognitive load of scanning large or subtle lesions frame by frame.

Importantly, the researchers emphasize that the algorithm does not replace clinical judgment. It is still the physician who makes the final diagnosis, weighing the AI-assisted image alongside the patient’s history, the appearance of the lesion and, where necessary, a conventional biopsy. The technology is best understood as a decision-support system: it directs attention to areas that merit closer scrutiny and can help distinguish malignant tissue from benign look-alikes, but accountability for the diagnostic decision remains with the treating clinician.

The clinical stakes of earlier detection are considerable. Basal cell carcinoma is a locally aggressive tumor: it spreads within the skin in its vicinity and destroys the tissue it invades, which can damage delicate structures such as the nose or the eyes when it arises on the face. Although it rarely metastasizes, its capacity for local destruction makes timely intervention essential. As Dr. Moritz Ronicke of FAU notes, detecting basal cell carcinoma early allows for less invasive treatment options, and in some cases all that is required is a medicated cream rather than surgical excision. Earlier and more confident diagnosis therefore translates directly into gentler treatment, better cosmetic outcomes and reduced burden on both patients and health systems.

The truly forward-looking element of the FAU work is a concept the researchers call SUBSCAN. Rather than imaging a lesion that has already attracted clinical suspicion, SUBSCAN would extend LC-OCT screening to people who carry a high risk of developing skin cancer but who do not yet have a visible tumor. In principle, the AI-assisted imaging could identify the microscopic signatures of basal cell carcinoma forming beneath an apparently normal skin surface, enabling a diagnosis even earlier in the disease process than current practice allows. If such risk-stratified optical screening were routinely adopted, Ronicke suggests, it could lead to more widespread use of topical creams for treating basal cell carcinoma, in some cases avoiding the need for surgery altogether.

That vision, however, is not yet ready for the clinic. The researchers are careful to point out that SUBSCAN cannot currently be offered routinely, for two principal reasons. First, there is still a lack of data on the sensitivity of the method, meaning it is not yet established how reliably the technique detects all early tumors and how often it might produce false alarms when applied to unselected high-risk skin. Second, the examination remains too time-consuming for routine deployment in a busy dermatology practice. Large prospective studies will be needed to quantify diagnostic performance, streamline the imaging workflow and define precisely which patient groups would benefit most from preventive scanning.

Even so, the trajectory of the technology is striking. Dermatology has been moving for years toward non-invasive diagnostics, from dermoscopy to reflectance confocal microscopy to OCT, each generation trading some simplicity for a deeper and sharper view of living skin. LC-OCT with AI-assisted image recognition represents a convergence of that trend: micrometer-scale, three-dimensional, real-time imaging paired with machine learning that distills complex optical data into an immediately interpretable probability map. For patients at elevated risk of skin cancer, the prospect of a diagnosis delivered before a tumor ever becomes visible, and of treatment with a simple cream instead of a scalpel, marks a compelling glimpse of where early cancer detection may be heading.

Subject of Research: AI-assisted line-field confocal optical coherence tomography for early detection of basal cell carcinoma

Article Title: Detecting skin cancer even before it becomes visible

Article References: Detecting skin cancer even before it becomes visible. (n.d.). Original publication

Image Credits: AI Generated

DOI: Not provided

Keywords: basal cell carcinoma, skin cancer, LC-OCT, optical coherence tomography, confocal microscopy, artificial intelligence, image recognition, early detection, non-invasive diagnosis, dermatology, JAMA Dermatology, SUBSCAN